Delphine Diagnostics, a New Jersey-based startup, is passionate about delivering top-tier diagnostic products and complementary data insights capabilities to enable speedy treatment for patients impacted by infectious diseases and admitted to hospital settings. As an example of the current status and impact, 350,000 people die due to sepsis-causing infections in the USA every year. As a forward-thinking medical diagnostics enterprise, Delphine Diagnostics aims to manufacture and supply certified testing kits to approved facilities, complemented by advanced artificial intelligence software applications. Our strategy will integrate these intelligent technologies to enhance diagnostic speed and accuracy while adhering to global best practices. This approach elevates the standard of our testing products and positions us at the forefront of technological innovation in healthcare diagnostics. The enterprise team is led by industry-experienced domain and business experts with service and ethical mindsets across biomedical sciences, data analytics, artificial intelligence, and market development.
Sepsis Diagnosis Test Kits:
As this ground-breaking diagnostic kit nears its development stage, its impact will be far-reaching, promising to revolutionize the field of infection diagnosis and treatment decision support. By expediting accurate diagnosis, tailoring treatments to individual patients, and optimizing antimicrobial usage, this novel technology holds the potential to save lives, improve patient care, and contribute to the global fight against antibiotic resistance.
Learn more: https://delphinedx.com/delphine-sepsis-panel-test/
-
所属行业
-
医疗设备制造业
-
规模
-
2-10 人
-
总部
-
Newark,NJ
-
类型
-
私人持股
-
创立
-
2020